Praluent (alirocumab) - Sanofi, Regeneron
miR-100-5p modulates postprandial triglyceride response by targeting PCSK9. (PubMed, Cardiovasc Res) - Oct 26, 2026 - "Taken together, our observations reveal that miR-100-5p regulates postprandial hypertriglyceridemia by targeting PCSK9, thus enhancing hepatic TGRL uptake. Our findings allow us to propose circ-miR-100-5p as a potential biomarker for early identification of subjects at high cardiovascular risk, prior to appearance of classical clinical features of metabolic disorders." 
Journal • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • MIR100
http://www.ncbi.nlm.nih.gov/pubmed/42910601
 
; Alexandre Motte; Amandine Vanduyse; Carolina Neves; Cédric Le May; Clément Materne; Eric Frisdal; Hervé Durand; Jean-Marc Lacorte; Joe-Elie Salem; Maryse Guerin; Olivier Bluteau; Philippe Giral; Philippe Lesnik; Rita Daclat; Sophie Galier; Wilfried Le Goff
 
Oct 26, 2026
 
Prev Next